Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беэр-Шева; 2 ГБОУ ВПО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310.
Список исп. литературыСкрыть список 1. Беккер РА, Быков ЮВ, Морозов ПВ. Выдающиеся психиатры XX века.М.:ИД Городец.– 2019.– 256 с. ISBN 978-5-907085-07-7. 2. Беккер РА, Быков ЮВ. Алимемазин: обзор применения. Психиатрия и психофармакотерапия. 2016;18(6):10-20. 3. Беккер РА, Быков ЮВ. Каликста® (миртазапин)-ценный терапевтический агент при резистентных депрессиях и не только. Обзор литературы с комментариями. Психиатрия и психофармакотерапия. 2019;21(5):36-49. 4. Беккер РА, Быков ЮВ. Клиническое применение перициазина (Неулептила). Психиатрия и психофармакотерапия. 2018;20(2):16-31. 5. Беккер РА, Быков ЮВ. Клоназепам: обзор новейших данных по применению. Психиатрия и психофармакотерапия. 2017;19(1):17-29. 6. Беккер РА, Быков ЮВ. Об эффективности и безопасности применения тразодона в лечении нейропсихиатрических последствий постковидного синдрома (Обзор литературы и представление двух клинических случаев). Психиатрия и психофармакотерапия. 2021;23(6):28–42. 7. Беккер РА, Быков ЮВ. Триттико® (тразодон) – уникальный серотонинергический антидепрессант с рядом дополнительных свойств. Психиатрия и психофармакотерапия. 2018;20(3–4):51–62. 8. Боброва ВИ, Демченко АВ. Пароксизмальное течение синдрома вегетативной дисфункции. Медицина неотложных состояний. 2017;8:87. 9. Быков ЮВ, Беккер РА, Резников МК. Депрессии и резистентность. Практическое руководство. М.: РИОР: ИНФРА-М., 2013. 374 с. ISBN 978-5-16-006093-4. 10. Быков ЮВ, Беккер РА. Пирроксан в психиатрии, неврологии и общесоматической медицине. Часть II. Психиатрия и психофармакотерапия. 2017;19(6):55-61. 11. Быков ЮВ, Беккер РА. Пророксан в наркологии и психиатрии (часть 1). Психиатрия и психофармакотерапия. 2017;19(2):44-51. 12. Быков ЮВ, Беккер РА. Хлорпротиксен: обзор применения в общесоматической практике и наркологии. Часть II. Психиатрия и психофармакотерапия. 2017;19(6):47-50. 13. Быков ЮВ, Беккер РА. Хлорпротиксен: обзор применения в психиатрии (I часть). Психиатрия и психофармакотерапия. 2016;18(2):26-32. 14. Жиляев АГ. Подходы к диагностике и лечению соматоформной вегетативной дисфункции. В кн.: Психическое здоровье человека XXI века. 2016. С. 254-257. 15. Мазо ГЭ, Незнанов НГ. Терапевтически резистентные депрессии. Санкт-Петербург.– 2012.– 448 с. ISBN 978-5-905225-48-2. 16. Медведев ВЭ, Морозов ПВ. Особенности применения снотворных препаратов у больных с кардиологической патологией. Актуальные вопросы болезней сердца и сосудов. 2006;2(1):50-52. 17. Монтгомери СА. Прегабалин при лечении генерализированного тревожного расстройства (расширенный реферат). Психические расстройства в общей медицине. 2010;1:3-6. 18. Морозов ПВ, Беккер РА, Быков ЮВ. Титаны психиатрии XX столетия. М.:ИД Городец.– 2020.– 488 с. ISBN 978-5-907085-64-0. 19. Морозов ПВ, Никитин ЗА. Гидроксизин (Атаракс) в современной психиатрической практике (обзор). Психиатрия и психофармакотерапия. 2009;11(2):29-32. 20. Наумов КМ, Золотарева НА, Балабанов АС, и др. Стресс-обусловленные функциональные вегетативные нарушения. Вестник Российской Военно-медицинской академии. 2020;(S3):141-141. 21. Петрова НН, Шагиахметов ФШ, Борукаев РР. Тразодон: грани клинической эффективности. Психиатрия и психофармакотерапия. 2021;3:40–46. 22. Чухловина МЛ. Особенности патогенеза, диагностики и лечения панических атак у лиц молодого возраста. Неврология, нейропсихиатрия, психосоматика. 2020;12(3):37-41. 23. Шабанов ПД. Клиническая фармакология пирроксана (пророксана). Обзоры по клинической фармакологии и лекарственной терапии. 2020;18(4):335-350. 24. Abramowitz JS, McKay D, Storch EA. The Wiley Handbook of Obsessive Compulsive Disorders (Wiley Clinical Psychology Handbooks). Wiley-Blackwell, 1st Ed, 2017. 1280 pages. ISBN 978-1118889640. 25. Ammar G, Naja WJ, Pelissolo A. Treatment-resistant anxiety disorders: A literature review of drug therapy strategies. Encephale. 2015;41(3):260-265. doi: 10.1016/j.encep.2013.11.002. 26. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249-264. doi: 10.1111/j.1527-3458.2001.tb00198.x. 27. Appl H, Holzammer T, Dove S et al. Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics. Naunyn Schmiedebergs Arch Pharmacol. 2012;385(2):145-170. doi: 10.1007/s00210-011-0704-0. 28. Back SE, Flanagan JC, Jones JL et al. Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans. Contemp Clin Trials. 2018;73:8-15. doi: 10.1016/j.cct.2018.08.009. 29. Belinskaia DA, Belinskaia MI, Barygin OI et al. Psychotropic Drugs for the Management of Chronic Pain and Itch. Pharmaceuticals (Basel). 2019;12(2):99. doi: 10.3390/ph12020099. 30. Bonazzi M, Riva A, Marsicano M et al. Trazodone versus flunitrazepam in premedication in day-care surgery. Minerva Anestesiol. 1994;60(3):115-121. 31. Bourgeois ML. Melancholy: from Hippocrates to DSM-IV. Rev Prat. 2002;52(8):821-824. 32. Carson AJ, Ringbauer B, Stone J et al. Do medically unexplained symptoms matter? A prospective cohort study of 300 new referrals to neurology outpatient clinics. J Neurol Neurosurg Psychiatry. 2000;68(2):207-210. doi: 10.1136/jnnp.68.2.207. 33. Centurión D, Ortiz MI, Saxena PR, Villalón CM. The atypical 5-HT2 receptor mediating tachycardia in pithed rats: pharmacological correlation with the 5-HT2A receptor subtype. Br J Pharmacol. 2002;135(6):1531-1539. doi: 10.1038/sj.bjp.0704593. 34. Charis C, Panayiotou G. Somatoform and Other Psychosomatic Disorders: A Dialogue Between Contemporary Psychodynamic Psychotherapy and Cognitive Behavioral Therapy Perspectives. Springer, 2018. 234 pages. ISBN 978-3319893617. 35. Clark BG, Araki M, Brown HW. Hydroxyzine-associated tardive dyskinesia. Ann Neurol. 1982;11(4):435. doi: 10.1002/ana.410110423. 36. Clifford EM, Gartside SE, Umbers V et al. Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo. Br J Pharmacol. 1998;124(1):206-212. doi: 10.1038/sj.bjp.0701796. 37. Crimlisk HL, Bhatia KP, Cope H et al. Patterns of referral in patients with medically unexplained motor symptoms. J Psychosom Res. 2000;49(3):217-219. doi: 10.1016/s0022-3999(00)00167-7. 38. Crocq MA. A history of anxiety: from Hippocrates to DSM. Dialogues Clin Neurosci. 2015;17(3):319-325. doi: 10.31887/DCNS.2015.17.3/macrocq. 39. Cuomo A, Ballerini A, Bruni AC et al. Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice. Riv Psichiatr. 2019;54(4):137-149. doi: 10.1708/3202.31796. 40. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994;114(4):559-565. doi: 10.1007/BF02244985. 41. Dabiré H. Central 5-hydroxytryptamine (5-HT) receptors in blood pressure regulation. Therapie. 1991;46(6):421-429. 42. Deveci A, Taskin O, Dinc G et al. Prevalence of pseudoneurologic conversion disorder in an urban community in Manisa, Turkey. Soc Psychiatry Psychiatr Epidemiol. 2007;42(11):857-864. doi: 10.1007/s00127-007-0233-9. 43. Doggrell SA. Increase in affinity and loss of 5-hydroxytryptamine2A-receptor reserve for 5-hydroxytryptamine on the aorta of spontaneously hypertensive rats. J Auton Pharmacol. 1995;15(5):371-377. doi: 10.1111/j.1474- 8673.1995.tb00403.x. 44. Dollie F. Psychiatric concepts in ancient Egyptian, Greco-Roman and Arabic civilizations. J Med Liban 1974;27(5):523-530. 45. ECNP Poster Session, 2020. Слайды доступны по адресу: https://ecnp33-ecnp.ipostersessions.com/Default.aspx?s=04-55-EA-52-BC-53-38-58-88-82-63-79-68-39-7B-... Доступ проверен 13.03.2021. 46. Elbers PG, Ozdemir A, van Iterson M et al. Microcirculatory imaging in cardiac anesthesia: ketanserin reduces blood pressure but not perfused capillary density. J Cardiothorac Vasc Anesth. 2009;23(1):95-101. doi: 10.1053/j.jvca.2008.09.013. 47. Esen I, Demirpence S, Yis U, Kurul S. Cetirizine-induced dystonic reaction in a 6-year-old boy. Pediatr Emerg Care. 2008;24(9):627-628. doi: 10.1097/PEC.0b013e3181850c35. 48. Fanciullacci M, Sicuteri R, Alessandri M, Geppetti P. Buspirone, but not sumatriptan, induces miosis in humans: relevance for a serotoninergic pupil control. Clin Pharmacol Ther. 1995;57(3):349-355. doi: 10.1016/0009-9236(95)90161-2. 49. Ganslev CA, Storebø OJ, Callesen HE et al. Psychosocial interventions for conversion and dissociative disorders in adults. Cochrane Database Syst Rev. 2020;7(7):CD005331. 50. Grégoire S, Neugebauer V. 5-HT2CR blockade in the amygdala conveys analgesic efficacy to SSRIs in a rat model of arthritis pain. Mol Pain. 2013;9:41. doi: 10.1186/1744-8069-9-41. 51. Gupta RK. Major depression: an illness with objective physical signs. World J Biol Psychiatry. 2009;10(3):196-201. doi: 10.1080/15622970902812072. 52. Haller H, Cramer H, Lauche R, Dobos G. Somatoform disorders and medically unexplained symptoms in primary care. Dtsch Arztebl Int. 2015;112(16):279-287. doi: 10.3238/arztebl.2015.0279. 53. Jaffer KY, Chang T, Vanle B et al. Trazodone for Insomnia: A Systematic Review. Innov Clin Neurosci. 2017;14(7-8):24-34. 54. Jensen NH, Rodriguiz RM, Caron MG et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303-2312. doi: 10.1038/sj.npp.1301646. 55. Jordan H, Ortiz N. Management of Insomnia and Anxiety in Myasthenia Gravis. J Neuropsychiatry Clin Neurosci. 2019;31(4):386-391. 56. Kaumann AJ, Levy FO. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther. 2006;111(3):674-706. doi: 10.1016/j.pharmthera.2005.12.004. 57. Kleinstäuber M, Witthöft M, Steffanowski A et al. Pharmacological interventions for somatoform disorders in adults. Cochrane Database Syst Rev. 2014;(11):CD010628. 58. Knobel M. The use of trazodone in psychosomatic medicine. Psychother Psychosom. 1974;24(2):141-145. 59. Kolassa N, Beller KD, Sanders KH. Involvement of brain 5-HT1A receptors in the hypotensive response to urapidil. Am J Cardiol. 1989;64(7):7D-10D. doi: 10.1016/0002-9149(89)90688-7. 60. Kranke P, Röhm KD, Diemunsch P et al. Intravenous buspirone for the prevention of postoperative nausea and vomiting. Eur J Clin Pharmacol. 2012;68(11):1465-1472. 61. Krystal AD, Richelson E, Roth T. Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications. Sleep Med Rev. 2013;17(4):263-72. doi: 10.1016/j.smrv.2012.08.001. 62. LeWitt PA, Walters A, Hening W, McHale D. Persistent movement disorders induced by buspirone. Mov Disord. 1993;8(3):331-334. doi: 10.1002/mds. 870080313. 63. Lipinska G, Baldwin DS, Thomas KF. Pharmacology for sleep disturbance in PTSD. Hum Psychopharmacol. 2016;31(2):156-63. doi: 10.1002/hup.2522. 64. Lucot JB. Antiemetic effects of flesinoxan in cats: comparisons with 8-hydroxy-2-(di-n-propylamino)tetralin. Eur J Pharmacol. 1994;253(1-2):53-60. 65. Maj M, Akiskal HS, Mezzich J, Okasha A. Somatoform Disorders (WPA Series in Evidence & Experience in Psychiatry Book 13). Wiley, 2005. 416 pages. ISBN 978-0470016121. 66. Meyer LR, Fuller A, Mitchell D. Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats. Am J Physiol Regul Integr Comp Physiol. 2006;290(2): R405-R413. doi: 10.1152/ajpregu.00440.2005. 67. Murphy LA, Barletta M, Graham LF et al. Effects of acepromazine and trazodone on anesthetic induction dose of propofol and cardiovascular variables in dogs undergoing general anesthesia for orthopedic surgery. J Am Vet Med Assoc. 2017;250(4):408-416. 68. Newman-Tancredi A, Chaput С, Gavaudan S et al. Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors. Neuropsychopharmacology. 1998;18(5):395-8. doi: 10.1016/S0893-133X(97)00169-3. 69. Nimnuan C, Hotopf M, Wessely S. Medically unexplained symptoms: an epidemiological study in seven specialities. J Psychosom Res. 2001;51(1):361-367. doi: 10.1016/s0022-3999(01)00223-9. 70. Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005;19(3):235-241. doi: 10.1177/0269881105051526. 71. Ohayon MM. Pain sensitivity, depression, and sleep deprivation: links with serotoninergic dysfunction. J Psychiatr Res. 2009;43(16):1243-1245. doi: 10.1016/j.jpsychires.2009.10.007. 72. Okasha A. Egyptian contribution to the concept of mental health. East Mediterr Health J. 2001;7(3):377-380. 73. Ootsuka Y, Blessing WW. Activation of 5-HT1A receptors in rostral medullary raphé inhibits cutaneous vasoconstriction elicited by cold exposure in rabbits. Brain Res. 2006;1073-1074:252-61. doi: 10.1016/j.brainres.2005. 12.031. 74. Oshima T, Kasuya Y, Okumura Y et al. Prevention of nausea and vomiting with tandospirone in adults after tympanoplasty. Anesth Analg. 2002;95(5):1442-1445. doi: 10.1097/00000539-200211000-00063. 75. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283(3):1305-1322. 76. Patterson JF. Akathisia associated with buspirone. J Clin Psychopharmacol. 1988;8(4):296-297. 77. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain--IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience. 1987;21(1):123-139. doi: 10.1016/0306-4522(87)90327-7. 78. Pieh C, Popp R, Geisler P, Hajak G. Sleep and pain: a bi-directional relation? Psychiatr Prax. 2011;38(4):166-170. doi: 10.1055/s-0030-1265949. 79. Pittenger C. Obsessive-compulsive Disorder: Phenomenology, Pathophysiology, and Treatment. Oxford University Press, 2017. 776 pages. ISBN 978-0190228163. 80. Pyke RE. Trazodone in Sexual Medicine: Underused and Overdosed? Sex Med Rev. 2020;8(2):206-216. doi: 10.1016/j.sxmr.2018.08.003. 81. Raffa RB, Shank RP, Vaught JL. Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity. Psychopharmacology (Berl). 1992;108(3):320-326. doi: 10.1007/BF02245118. 82. Ramage AG. The mechanism of the sympathoinhibitory action of urapidil: role of 5-HT1A receptors. Br J Pharmacol. 1991;102(4):998-1002. doi: 10.1111/j.1476-5381.1991.tb12290.x. 83. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984;230(1):94-102. 84. Ritchie EC, Bridenbaugh RH, Jabbari B. Acute generalized myoclonus following buspirone administration. J Clin Psychiatry. 1988;49(6):242-243. 85. Rusyniak DE, Zaretskaia MV, Zaretsky DV, DiMicco JA. 3,4-Methylenedioxymethamphetamine- and 8-hydroxy-2-di-n-propylamino-tetralin-induced hypothermia: role and location of 5-hydroxytryptamine 1A receptors. J Pharmacol Exp Ther. 2007;323(2):477-87. doi: 10.1124/jpet.107.126169. 86. Sadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry (2 Volume Set). 10th edition. Lippincott Williams and Wilkins; 2017. 4997p. ISBN 978-1451100471. 87. Saletu B, Prause W, Anderer P et al. Insomnia in somatoform pain disorder: sleep laboratory studies on differences to controls and acute effects of trazodone, evaluated by the Somnolyzer 24 x 7 and the Siesta database. Neuropsychobiology. 2005;51(3):148-163. doi: 10.1159/000085207. 88. Schotte A, Janssen PF, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124(1-2):57-73. doi: 10.1007/BF02245606. 89. Settimo L, Taylor D. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets. J Psychopharmacol. 2018;32(1):96-104. doi: 10.1177/0269881117742101. 90. Shuman MD, Mcgrane IR. Rationale for iloperidone in the treatment of posttraumatic stress disorder. Innov Clin Neurosci. 2014;11(5-6):23-25. 91. Sinh S, Ootsuka Y. Blockade of 5-HT2A receptors inhibits emotional hyperthermia in mice. J Physiol Sci. 2019;69(6):1097-1102. doi: 10.1007/s12576-019-00703-7. 92. Skelly MJ, Weiner JL. Chronic treatment with prazosin or duloxetine lessens concurrent anxiety-like behavior and alcohol intake: evidence of disrupted noradrenergic signaling in anxiety-related alcohol use. Brain Behav. 2014;4(4):468-83. doi: 10.1002/brb3.230. 93. Snijders TJ, de Leeuw FE, Klumpers UH et al. Prevalence and predictors of unexplained neurological symptoms in an academic neurology outpatient clinic--an observational study. J Neurol. 2004;251(1):66-71. doi: 10.1007/s00415-004-0273-y. 94. Snowman AM, Snyder SH. Cetirizine: actions on neurotransmitter receptors. J Allergy Clin Immunol. 1990;86(6 Pt 2):1025-1028. 95. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009;14(10):536-546. doi: 10.1017/s1092852900024020. 96. Stahl SM. Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr. 2013;18(6):285-288. doi: 10.1017/S1092852913000850. 97. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge university press, 2013. 626 p. ISBN 978-1107686465. 98. Stefánsson JG, Messina JA, Meyerowitz S. Hysterical neurosis, conversion type: clinical and epidemiological considerations. Acta Psychiatr Scand. 1976;53(2):119-138. doi: 10.1111/j.1600-0447.1976.tb00066.x. 99. Stone J, Carson A, Sharpe M. Functional symptoms and signs in neurology: assessment and diagnosis. J Neurol Neurosurg Psychiatry. 2005;76 Suppl 1(Suppl 1):i2-12. doi: 10.1136/jnnp.2004.061655. 100. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340(2-3):249-258. doi: 10.1016/s0014-2999(97)01393-9. 101. Wang YX, Ren ZH, Wang SJ. A double‐blind study on trazodone in the treatment of persistent somatoform pain disorder. Chinese Journal of Pain Medicine. 2003;9(2):70-72. 102. Xu WJ, Wang Y, Zhao Y et al. Involvement of 5-HT2A, 5-HT2B and 5-HT2C receptors in mediating the ventrolateral orbital cortex-induced antiallodynia in a rat model of neuropathic pain. Neuroreport. 2020;31(2): 167-173. doi: 10.1097/WNR.0000000000001377.